Original Research
Accepted on 13 Apr 2026
Cost-effectiveness analysis of Atezolizumab plus Bevacizumab versus Rivoceranib plus Camrelizumab as first-line treatment for unresectable hepatocellular carcinoma
in Health System Economics and Financing
Frontiers in Health Services
- 1,029 views

